ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis

Rebecca S. Cook, Joan T. Garrett, Violeta Sánchez, Jamie C. Stanford, Christian Young, Anindita Chakrabarty, Cammie Rinehart, Yixian Zhang, Yaming Wu, Lee Greenberger, Ivan D. Horak, Carlos L. Arteaga

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The ErbB receptor family member ErbB3 has been implicated in breast cancer growth, but it has yet to be determined whether its disruption is therapeutically valuable. In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth. In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib. Thus, full engagement of PI3K/Akt by ErbB2 in this oncogene-induced mouse tumor model may involve its ability to dimerize with and phosphorylate ErbB3, which itself directly binds PI3K. In this article, we report that ErbB3 is critical for PI3K/Akt-driven tumor formation triggered by the PyVmT oncogene. Tissue-specific, Cre-mediated deletion of ErbB3 reduced Akt phosphorylation, primary tumor growth, and pulmonary metastasis. Furthermore, EZN-3920, a chemically stabilized antisense oligonucleotide that targets the ErbB3 mRNA in vivo, produced similar effects while causing no toxicity in the mouse model. Our findings offer further preclinical evidence that ErbB3 ablation may be therapeutically effective in tumors where ErbB3 engages PI3K/Akt signaling.

Original languageEnglish (US)
Pages (from-to)3941-3951
Number of pages11
JournalCancer Research
Volume71
Issue number11
DOIs
StatePublished - Jun 1 2011

Fingerprint

Phosphatidylinositol 3-Kinase
Carcinogenesis
Breast
Polyomavirus
Oncogenes
Neoplasms
Growth
Breast Neoplasms
Aptitude
Antisense Oligonucleotides
Protein-Tyrosine Kinases
Phosphorylation
Neoplasm Metastasis
Lung
Messenger RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cook, R. S., Garrett, J. T., Sánchez, V., Stanford, J. C., Young, C., Chakrabarty, A., ... Arteaga, C. L. (2011). ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Research, 71(11), 3941-3951. https://doi.org/10.1158/0008-5472.CAN-10-3775

ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. / Cook, Rebecca S.; Garrett, Joan T.; Sánchez, Violeta; Stanford, Jamie C.; Young, Christian; Chakrabarty, Anindita; Rinehart, Cammie; Zhang, Yixian; Wu, Yaming; Greenberger, Lee; Horak, Ivan D.; Arteaga, Carlos L.

In: Cancer Research, Vol. 71, No. 11, 01.06.2011, p. 3941-3951.

Research output: Contribution to journalArticle

Cook, RS, Garrett, JT, Sánchez, V, Stanford, JC, Young, C, Chakrabarty, A, Rinehart, C, Zhang, Y, Wu, Y, Greenberger, L, Horak, ID & Arteaga, CL 2011, 'ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis', Cancer Research, vol. 71, no. 11, pp. 3941-3951. https://doi.org/10.1158/0008-5472.CAN-10-3775
Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Research. 2011 Jun 1;71(11):3941-3951. https://doi.org/10.1158/0008-5472.CAN-10-3775
Cook, Rebecca S. ; Garrett, Joan T. ; Sánchez, Violeta ; Stanford, Jamie C. ; Young, Christian ; Chakrabarty, Anindita ; Rinehart, Cammie ; Zhang, Yixian ; Wu, Yaming ; Greenberger, Lee ; Horak, Ivan D. ; Arteaga, Carlos L. / ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. In: Cancer Research. 2011 ; Vol. 71, No. 11. pp. 3941-3951.
@article{5448d516858e454fad0521c85c4a15f8,
title = "ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis",
abstract = "The ErbB receptor family member ErbB3 has been implicated in breast cancer growth, but it has yet to be determined whether its disruption is therapeutically valuable. In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth. In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib. Thus, full engagement of PI3K/Akt by ErbB2 in this oncogene-induced mouse tumor model may involve its ability to dimerize with and phosphorylate ErbB3, which itself directly binds PI3K. In this article, we report that ErbB3 is critical for PI3K/Akt-driven tumor formation triggered by the PyVmT oncogene. Tissue-specific, Cre-mediated deletion of ErbB3 reduced Akt phosphorylation, primary tumor growth, and pulmonary metastasis. Furthermore, EZN-3920, a chemically stabilized antisense oligonucleotide that targets the ErbB3 mRNA in vivo, produced similar effects while causing no toxicity in the mouse model. Our findings offer further preclinical evidence that ErbB3 ablation may be therapeutically effective in tumors where ErbB3 engages PI3K/Akt signaling.",
author = "Cook, {Rebecca S.} and Garrett, {Joan T.} and Violeta S{\'a}nchez and Stanford, {Jamie C.} and Christian Young and Anindita Chakrabarty and Cammie Rinehart and Yixian Zhang and Yaming Wu and Lee Greenberger and Horak, {Ivan D.} and Arteaga, {Carlos L.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-10-3775",
language = "English (US)",
volume = "71",
pages = "3941--3951",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis

AU - Cook, Rebecca S.

AU - Garrett, Joan T.

AU - Sánchez, Violeta

AU - Stanford, Jamie C.

AU - Young, Christian

AU - Chakrabarty, Anindita

AU - Rinehart, Cammie

AU - Zhang, Yixian

AU - Wu, Yaming

AU - Greenberger, Lee

AU - Horak, Ivan D.

AU - Arteaga, Carlos L.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - The ErbB receptor family member ErbB3 has been implicated in breast cancer growth, but it has yet to be determined whether its disruption is therapeutically valuable. In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth. In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib. Thus, full engagement of PI3K/Akt by ErbB2 in this oncogene-induced mouse tumor model may involve its ability to dimerize with and phosphorylate ErbB3, which itself directly binds PI3K. In this article, we report that ErbB3 is critical for PI3K/Akt-driven tumor formation triggered by the PyVmT oncogene. Tissue-specific, Cre-mediated deletion of ErbB3 reduced Akt phosphorylation, primary tumor growth, and pulmonary metastasis. Furthermore, EZN-3920, a chemically stabilized antisense oligonucleotide that targets the ErbB3 mRNA in vivo, produced similar effects while causing no toxicity in the mouse model. Our findings offer further preclinical evidence that ErbB3 ablation may be therapeutically effective in tumors where ErbB3 engages PI3K/Akt signaling.

AB - The ErbB receptor family member ErbB3 has been implicated in breast cancer growth, but it has yet to be determined whether its disruption is therapeutically valuable. In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth. In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib. Thus, full engagement of PI3K/Akt by ErbB2 in this oncogene-induced mouse tumor model may involve its ability to dimerize with and phosphorylate ErbB3, which itself directly binds PI3K. In this article, we report that ErbB3 is critical for PI3K/Akt-driven tumor formation triggered by the PyVmT oncogene. Tissue-specific, Cre-mediated deletion of ErbB3 reduced Akt phosphorylation, primary tumor growth, and pulmonary metastasis. Furthermore, EZN-3920, a chemically stabilized antisense oligonucleotide that targets the ErbB3 mRNA in vivo, produced similar effects while causing no toxicity in the mouse model. Our findings offer further preclinical evidence that ErbB3 ablation may be therapeutically effective in tumors where ErbB3 engages PI3K/Akt signaling.

UR - http://www.scopus.com/inward/record.url?scp=79957915754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957915754&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-3775

DO - 10.1158/0008-5472.CAN-10-3775

M3 - Article

VL - 71

SP - 3941

EP - 3951

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -